It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Pseudomonas aeruginosa is a major nosocomial pathogen that causes severe disease including sepsis. Carbapenem-resistant P. aeruginosa is recognised by the World Health Organisation as a priority 1 pathogen, with urgent need for new therapeutics. As such, there is renewed interest in using bacteriophages as a therapeutic. However, the dynamics of treating pan-resistant P. aeruginosa with phage in vivo are poorly understood. Using a pan-resistant P. aeruginosa in vivo infection model, phage therapy displays strong therapeutic potential, clearing infection from the blood, kidneys, and spleen. Remaining bacteria in the lungs and liver displays phage resistance due to limiting phage adsorption. Yet, resistance to phage results in re-sensitisation to a wide range of antibiotics. In this work, we use phage steering in vivo, pre-exposing a pan resistant P. aeruginosa infection with a phage cocktail to re-sensitise bacteria to antibiotics, clearing the infection from all organs.
In this work, authors utilise a pan-resistant Pseudomonas aeruginosa in vivo infection model to demonstrate antibiotic re-sensitisation with bacteriophage therapy.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 University of Liverpool, Department of Clinical Infection, Microbiology and Immunology, Liverpool, UK (GRID:grid.10025.36) (ISNI:0000 0004 1936 8470)
2 University of Manchester, Division of Evolution & Genomic Sciences, School of Biological Sciences, Manchester, UK (GRID:grid.5379.8) (ISNI:0000 0001 2166 2407)
3 University of Liverpool, Department of Clinical Infection, Microbiology and Immunology, Liverpool, UK (GRID:grid.10025.36) (ISNI:0000 0004 1936 8470); Manchester Metropolitan University, Centre for Bioscience, Manchester, UK (GRID:grid.25627.34) (ISNI:0000 0001 0790 5329)
4 University of Liverpool, Department of Evolution, Ecology and Behaviour, Liverpool, UK (GRID:grid.10025.36) (ISNI:0000 0004 1936 8470)